{"schema_version":"secwatch.filing_event.v1","accession":"0001651308-26-000025","form_type":"8-K","ticker":"ONC","cik":"0001651308","company_name":"BeOne Medicines Ltd.","filed_at":"2026-08-26T10:14:58+00:00","discovered_at":"2026-08-26T10:20:01.593710+00:00","generated_at":"2026-08-26T10:20:16.927380+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"high","headline":"BeOne Medicines discloses H1 2026 R&D spend of $1.15B, up 14.6% YoY","bullets":["Total R&D expense $1,153.5M in H1 2026 vs $1,006.8M in H1 2025, up 14.6% YoY.","BRUKINSA R&D fell 33% to $42.7M from $63.0M; TEVIMRA down to $37.1M from $40.3M.","BEQALZI (sonrotoclax) R&D $74.0M, down 21%; BGB-43395 CDK4 inhibitor surged to $22.7M vs $9.9M.","Early-stage spend jumped: BGB-58067 $11.1M vs $1.9M, BG-C9074 $8.2M vs $2.4M, tacabrutideg $44.3M vs $26.9M.","External R&D $435.1M vs $400.3M; internal R&D $718.4M vs $606.5M a year ago."],"urls":{"canonical":"https://secwatch.observer/filing/0001651308-26-000025","json":"https://secwatch.observer/filing/0001651308-26-000025.json","markdown":"https://secwatch.observer/filing/0001651308-26-000025.md","text":"https://secwatch.observer/filing/0001651308-26-000025.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1651308/000165130826000025/0001651308-26-000025-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1651308/000165130826000025/bgne-20260826.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-08-26T10:20:16.927380+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}